1. Home
  2. MDGL

as 06-18-2025 11:38am EST

$
-
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Founded: 2011 Country:
United States
United States
Employees: N/A City: WEST CONSHOHOCKEN
Market Cap: 6.1B IPO Year: N/A
Target Price: $420.63 AVG Volume (30 days): 306.7K
Analyst Decision: Strong Buy Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -17.97 EPS Growth: N/A
52 Week Low/High: $200.63 - $377.46 Next Earning Date: 08-06-2025
Revenue: $317,383,000 Revenue Growth: N/A
Revenue Growth (this year): 286.17% Revenue Growth (next year): 64.17%

MDGL Daily Stock ML Predictions

Share on Social Networks: